Evolus (EOLS) Stock Forecast, Price & News

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Evolus in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" EOLS shares.
View EOLS analyst ratings or view top-rated stocks.

4 equities research analysts have issued 12 month price targets for Evolus' shares. Their EOLS share price forecasts range from $18.00 to $27.00. On average, they anticipate the company's stock price to reach $21.40 in the next year. This suggests a possible upside of 146.8% from the stock's current price.
View analysts price targets for EOLS or view top-rated stocks among Wall Street analysts.

Evolus' stock was trading at $7.51 at the beginning of the year. Since then, EOLS shares have increased by 15.4% and is now trading at $8.67.
View the best growth stocks for 2023 here.

Evolus saw a increase in short interest in the month of September. As of September 15th, there was short interest totaling 3,560,000 shares, an increase of 5.3% from the August 31st total of 3,380,000 shares. Based on an average daily trading volume, of 571,100 shares, the short-interest ratio is currently 6.2 days. Approximately 8.4% of the company's shares are sold short.
View Evolus' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 14th 2023.
View our EOLS earnings forecast.

Evolus, Inc. (NASDAQ:EOLS) posted its quarterly earnings results on Wednesday, August, 2nd. The company reported ($0.28) earnings per share for the quarter, missing the consensus estimate of ($0.26) by $0.02. The company earned $49.35 million during the quarter, compared to analyst estimates of $46.12 million. Evolus had a negative net margin of 39.36% and a negative trailing twelve-month return on equity of 507.42%.

Evolus updated its FY 2023 earnings guidance on Thursday, July, 27th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $185.00 million-$195.00 million, compared to the consensus revenue estimate of $187.83 million.

1 employees have rated Evolus Chief Executive Officer David Moatazedi on Glassdoor.com. David Moatazedi has an approval rating of 100% among the company's employees. This puts David Moatazedi in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Evolus investors own include Celadon Group (CGI), ADMA Biologics (ADMA), Chesapeake Energy (CHKAQ), Matinas BioPharma (MTNB), Advanced Micro Devices (AMD), Dynavax Technologies (DVAX), Sorrento Therapeutics (SRNE), Aldeyra Therapeutics (ALDX), Organigram (OGI) and Bionano Genomics (BNGO).

(EOLS) raised $65 million in an initial public offering on Thursday, February 8th 2018. The company issued 5,000,000 shares at $12.00-$14.00 per share. Cantor and Mizuho Securities served as the underwriters for the IPO and SunTrust Robinson Humphrey and JMP Securities were co-managers.

Evolus trades on the NASDAQ under the ticker symbol "EOLS."

Shares of EOLS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of EOLS stock can currently be purchased for approximately $8.67.

Evolus (NASDAQ:EOLS) has a market capitalization of $493.93 million and generates $148.62 million in revenue each year. The company earns $-74,410,000.00 in net income (profit) each year or ($1.17) on an earnings per share basis.

The company employs 215 workers across the globe.

Evolus' mailing address is 520 Newport Center Dr. Suite 1200, Newport Beach CA, 92660. The official website for the company is www.evolus.com. The company can be reached via phone at (949) 284-4555 or via email at ir@evolus.com.